Skip to main content

Table 2 Optimization of ARVs in the three countries of Latin America, 2012-2013

From: Progress and challenges in implementing HIV care and treatment policies in Latin America following the treatment 2.0 initiative

INDICATOR

Year

El Salvador

Venezuela

Bolivia

Mean

Number of first-line ART regimens in use

2012

11

14

9

11

2013

12

4

6

7

Percentage of patients in the preferred first-line ART regimens recommended by WHO (TDF + 3TC (or FTC) + EFV)

2012

85 %

39 %

98 %

74 %

2013

92 %

43 %

99 %

78 %

Percentage of patients in the preferred first-line ART regimens recommended by WHO (TDF + 3TC [or FTC] + EFV)

2012

9 %

63 %

37 %

36 %

2013

20 %

43 %

66 %

43 %

Percentage of patients in first-line ART regimens including obsolete antiretrovirals (ddl, d4T, IDV, NFV)

2012

13 %

0 %

1 %

5 %

2013

2 %

0 %

0 %

1 %

Number of second-line ART regimens in use

2012

8 %

18 %

8 %

11 %

2013

10 %

4 %

7 %

7 %

Percentage of patients in second-line ART regimens recommended by WHO

2012

55 %

0 %

74 %

43 %

2013

64 %

50 %

83 %

65 %

Percentage of patients in second-line ART regimens including obsolete ARVs

2012

35 %

1 %

19 %

18 %

2013

20 %

0 %

8 %

9 %

  1. TDF tenofovir dispoproxil fumarate, 3TC lamivudine, FTC emtricitabine, EFV efavirenz, ddl didanosine, d4T Stavudine, IDV indinavir, NFV nelfinavir, WHO World Health Organization, ARVs antiretrovirals